Clinical Trial Update: Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update indicates withdrawal of a Phase 1/Phase 2 induction therapy trial using carfilzomib, lenalidomide, dexamethasone, and panobinostat fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Decadron (Dexamethasone)
• Farydak (panobinostat)
• Kyprolis (carfilzomib)
• Revlimid (lenalidomide)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: WITHDRAWN